Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) · doi:10.1101/2021.06.01.21258172 · Cited by 425

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., Graham, M. S., Klaser, K., Modat, M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00460-6 · Cited by 843

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

Antonelli, M., Penfold, R., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L., Graham, M. S., Kläser, K., Marc Modat, A., et al. (2022) · UCL Discovery (University College London) · Cited by 512

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 319

Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study

Nordström, P., Ballin, M., & Nordström, A. (2021) · The Lancet · doi:10.1016/s0140-6736(22)00089-7 · Cited by 341

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study

Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S., & Patalon, T. (2021) · Nature Communications · doi:10.1038/s41467-021-26672-3 · Cited by 261

COVID-19 vaccination: The road ahead

Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 198

Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events

Ng, S. C., Peng, Y., Zhang, L., Mok, C. K. P., Zhao, S., Li, A., Ching, J. Y. L., Liu, Y., Yan, S., Chan, D. L. S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326563 · Cited by 186

Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs

Seneff, S., Nigh, G., Kyriakopoulos, A. M., & McCullough, P. A. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113008 · Cited by 182

Population antibody responses following COVID-19 vaccination in 212,102 individuals

Ward, H., Whitaker, M. D., Flower, B., Tang, S. N., Atchison, C. J., Darzi, A. W., Donnelly, C. A., Cann, A., Diggle, P. J., Ashby, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28527-x · Cited by 169

COVID ‐19 Vaccine Response in People with Multiple Sclerosis

Tallantyre, E. C., Vickaryous, N. K., Anderson, V. M., Asardag, A. N., Baker, D., Bestwick, J. P., Bramhall, K., Chance, R., Evangelou, N., George, K., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26251 · Cited by 158

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland

Rzymski, P., Poniedziałek, B., & Fal, A. (2021) · Vaccines · doi:10.3390/vaccines9111286 · Cited by 160

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 145

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

Patalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., & Weinberger, D. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7382 · Cited by 141

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 133

Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine

Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00373-7 · Cited by 123

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil

Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02754-9 · Cited by 124

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103904 · Cited by 122

COVID vaccine boosters: the most important questions

Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-02158-6 · Cited by 109

COVID-19 Vaccine Booster: To Boost or Not to Boost

Shekhar, R., Garg, I., Pal, S., Kottewar, S., & Sheikh, A. B. (2021) · Infectious Disease Reports · doi:10.3390/idr13040084 · Cited by 108

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Seoane, R. C., Kottoor, S. H., Pieper, F. P., Lin, K., Butler, D. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28517-z · Cited by 103

Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review

Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 95

Immune recall improves antibody durability and breadth to SARS-CoV-2 variants

Chen, Y., Tong, P., Whiteman, N. B., Moghaddam, A. S., Zarghami, M., Zuiani, A., Habibi, S., Gautam, A. K., Keerti, K., Bi, C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8328 · Cited by 89

mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine

Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 90

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study

Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort

Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 84

COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly

Rzymski, P., Camargo, C. A., Fal, A., Flisiak, R., Gwenzi, W., Kelishadi, R., Leemans, A., Nieto, J. J., Ozen, A., Perc, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111299 · Cited by 76

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges

Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 78

Metabolic disorders, COVID-19 and vaccine-breakthrough infections

Stefan, N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00608-9 · Cited by 71

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

Glatman-Freedman, A., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan-Boker, L., & Bromberg, M. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2711.211886 · Cited by 70

Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls

Čalušić, M., Marčec, R., Luksa, L., Jurkovic, I., Kovač, N., Mihaljević, S., & Likić, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15126 · Cited by 68

Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69

Defending against SARS-CoV-2: The T cell perspective

Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67

Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines

Fraser, R., Resendiz, A. O., Mazein, A., & Dockrell, D. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.01.003 · Cited by 61

Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination

Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 60

A Narrative Review of COVID-19 Vaccines

Eroglu, B., Nuwarda, R. F., Ramzan, I. M., & Kayser, V. (2021) · Vaccines · doi:10.3390/vaccines10010062 · Cited by 59

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Bonelli, M. M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221558 · Cited by 61

Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study

Selma‐Royo, M., Bäuerl, C., Tudela, D. M., Aguilar‐Camprubí, L., Pérez-Cano, F. J., Llorca, A. P., Lerín, C., Martínez‐Costa, C., & Collado, M. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01043-9 · Cited by 65

Post COVID-19 condition of the Omicron variant of SARS-CoV-2

Morioka, S., Tsuzuki, S., Suzuki, M., Terada, M., Akashi, M., Osanai, Y., Kuge, C., Sanada, M., Tanaka, K., Maruki, T., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.08.007 · Cited by 61

Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions

Krasselt, M., Wagner, U. G., Nguyen, P., Pietsch, C., Boldt, A., Baerwald, C., Pierer, M., & Seifert, O. (2022) · Rheumatology · doi:10.1093/rheumatology/keac089 · Cited by 57

A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity

Cafferty, S. M., Haque, A. K. M. A., Vandierendonck, A., Weidensee, B., Plovyt, M., Stuchlíková, M., François, N., Valembois, S., Heyndríckx, L., Míchiels, J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.014 · Cited by 56

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

Huang, A., Cicin‐Sain, C., Pasin, C., Epp, S., Audigé, A., Mueller, N. J., Nilsson, J., Bankova, A. K., Wolfensberger, N., Vilinovszki, O., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.019 · Cited by 55

The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data

Glatman‐Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y., & Keinan‐Boker, L. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103574 · Cited by 52

Covid-19: virology, variants, and vaccines

Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 55

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review

Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 58

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Benning, L., Morath, C. P., Bartenschlager, M., Kim, H., Reineke, M., Beimler, J., Buylaert, M., Nußhag, C., Kälble, F., Reichel, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17054 · Cited by 51

Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic

Altındiş, E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2014819 · Cited by 50

IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers

Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., Caffau, C., Vettori, R., Cozzi, M. R., Zanussi, S., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.035 · Cited by 48

Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization

Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 49

Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls

Caldera, F., Knutson, K. L., Saha, S., Wald, A. M., Phan, H., Chun, K., Grimes, I. C., Lutz, M. K., Hayney, M. S., & Farraye, F. A. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001570 · Cited by 49

Adapting Serosurveys for the SARS-CoV-2 Vaccine Era

Duarte, N., Yanes‐Lane, M., Arora, R. K., Bobrovitz, N., Liu, M., Bego, M. G., Yan, T., Cao, C., Gurry, C., Hankins, C. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab632 · Cited by 46

A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients

Sakuraba, A., Luna, A., & Micić, D. (2022) · Viruses · doi:10.3390/v14081822 · Cited by 45

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis

Farroni, C., Diamanti, A. P., Aiello, A., Nicastri, E., Laganà, B., Agrati, C., Castilletti, C., Meschi, S., Colavita, F., Cuzzi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846753 · Cited by 46

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis

Cheng, H., Peng, Z., Si, S., Alifu, X., Zhou, H., Chi, P., Zhuang, Y., Mo, M., & Yu, Y. (2022) · Vaccines · doi:10.3390/vaccines10050798 · Cited by 43

Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods

Anastassopoulou, C. G., Antoni, D., Manoussopoulos, Y. N., Stefanou, P., Argyropoulou, S., Vrioni, G., & Tsakris, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266958 · Cited by 42

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks

Speer, C., Schaier, M., Nußhag, C., Töllner, M., Buylaert, M., Kälble, F., Reichel, P., Grenz, J., Süsal, C., Zeier, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9101130 · Cited by 41

Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines

Choudhary, H. R., Parai, D., Dash, G. C., Kshatri, J. S., Mishra, N., Choudhary, P. K., Pattnaik, D., Panigrahi, K., Behera, S., Sahoo, N. R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.778129 · Cited by 42

Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)

Basso, P., Negro, C., Cegolon, L., & Filon, F. L. (2022) · Viruses · doi:10.3390/v14020336 · Cited by 43

Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants

Vadrevu, K. M., Ganneru, B., Reddy, S., Jogdand, H., Raju, D., Praturi, U., Sapkal, G. N., Yadav, P. D., Reddy, P., Verma, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16097-3 · Cited by 39

Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study

Amellal, H., Assaid, N., Charoute, H., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288557 · Cited by 40

Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies

Cheetham, N. J., Kibble, M., Wong, A., Silverwood, R. J., Knüppel, A., Williams, D. M., Hamilton, O. K., Lee, P. H., Staatz, C. B., Gessa, G. D., et al. (2023) · eLife · doi:10.7554/elife.80428 · Cited by 40

Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults

Erice, A., Varillas‐Delgado, D., & Caballero, C. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.023 · Cited by 39

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 36

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)

Sunagar, R., Prasad, S. D., Ella, R., & Vadrevu, K. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063679 · Cited by 38

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

Zhao, W., Chen, W., Li, J., Chen, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2022) · mBio · doi:10.1128/mbio.00181-22 · Cited by 37

Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina

Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M. E., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100123 · Cited by 37

Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis

Ebinger, J. E., Joung, S. Y., Liu, Y., Wu, M., Weber, B., Claggett, B. L., Botting, P. G., Sun, N., Driver, M. P., Kao, Y. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059994 · Cited by 34

Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination

Huang, L., Li, Y., Luo, C., Chen, Y., Touil, N., Annaz, H. E., Zeng, S., Dang, T., Liang, J., Hu, W., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113868 · Cited by 36

Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis

Sakuraba, A., Luna, A., & Micić, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01233-3 · Cited by 36

Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study

Furer, V., Eviatar, T., Freund, T., Peleg, H., Paran, D., Levartovsky, D., Kaufman, I., Broyde, A., Elalouf, O., Polachek, A., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222550 · Cited by 38

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers

Marking, U. W., Havervall, S., Greilert‐Norin, N., Bladh, O., Christ, W., Gordon, M., Ng, H., Blom, K. G., Phillipson, M., Mangsbo, S. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36984-1 · Cited by 45

Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus

Ye, T., Zhou, J., Guo, C., Zhang, K., Wang, Y., Liu, Y., Zhou, J., Xie, Y., Li, E., Gong, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114269 · Cited by 35

mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship

Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 33

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

Schmiedeberg, K., Vuilleumier, N., Pagano, S., Albrich, W. C., Ludewig, B., von Kempis, J., & Rubbert-Roth, A. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00328-3 · Cited by 33

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 31

Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals

Lechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine

Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.621 · Cited by 55

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 33

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialPreprint

Li, M., Yang, J., Wang, L., Wu, Q., Wu, Z., Zheng, W., Wang, L., Lu, W., Deng, X., Peng, C., et al. (2021) · medRxiv · doi:10.1101/2021.08.03.21261544 · Cited by 32

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint

Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety

Meng, H., Mao, J., & Ye, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27590 · Cited by 35

The association between social media use and hesitancy toward COVID-19 vaccine booster shots in China: A web-based cross-sectional survey

Wang, R., Qin, C., Du, M., Liu, Q., Tao, L., & Liu, J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2065167 · Cited by 36

Effectiveness of COVID‑19 vaccines and their challenges (Review)

Marfè, G., Perna, S., & Shukla, A. K. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10843 · Cited by 32

Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland

Babicki, M., & Mastalerz–Migas, A. (2022) · Vaccines · doi:10.3390/vaccines10010068 · Cited by 31

Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly

Ferreira, I. A. T. M., Lee, C. Y. C., Foster, W. S., Abdullahi, A., Dratva, L. M., Tuong, Z. K., Stewart, B. J., Ferdinand, J. R., Guillaume, S. M., Potts, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112991 · Cited by 30

SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers

Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Pezzani, M. D., Lippi, G., Gibellini, D., Tacconelli, E., Vecchia, I. D., Sala, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081193 · Cited by 30

Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults

Nishimi, K. M., Neylan, T. C., Bertenthal, D., Seal, K. H., & O’Donovan, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7287 · Cited by 30

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103448 · Cited by 31

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individualsPreprint

Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Tanussiya, S., Kuruppu, H., Ranasinghe, T., et al. (2021) · medRxiv · doi:10.1101/2021.10.14.21265030 · Cited by 30

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Syversen, S. W., Jyssum, I., Tveter, A. T., Sexton, J., Christensen, I. E., Tran, T. T., Bjørlykke, K. H., Mjaaland, S., Warren, D. J., Kvien, T. K., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002417 · Cited by 29

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

Jo, D. H., Minn, D., Lim, J., Lee, K.-D., Kang, Y. M., Choe, K. W., & Kim, K. N. (2021) · Vaccines · doi:10.3390/vaccines9101145 · Cited by 32

Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months

Ponticelli, D., Antonazzo, I. C., Caci, G., Vitale, A., Ragione, G. D., Romano, M. L., Borrelli, M., Schiavone, B., Polosa, R., & Ferrara, P. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab173 · Cited by 28

Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing

Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 27

Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time

Havervall, S., Marking, U. W., Greilert‐Norin, N., Gordon, M., Ng, H., Christ, W., Phillipson, M., Nilsson, P., Hober, S., Blom, K. G., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1388 · Cited by 24

Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response

Pušnik, J., König, J., Mai, K., Richter, E., Zorn, J., Proksch, H., Schulte, B., Alter, G., & Streeck, H. (2022) · Journal of Virology · doi:10.1128/jvi.00760-22 · Cited by 29

Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases

Gao, X., Wang, X., Li, S., Rahman, M. S. U., Xu, S., & Liu, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07741 · Cited by 27

Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination

Rieke, G. J., van Bremen, K., Bischoff, J., ToVinh, M., Monin, M. B., Schlabe, S., Raabe, J., Kaiser, K. M., Finnemann, C., Odainic, A., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac060 · Cited by 25

COVID-19 Vaccination and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in the European Economic Area during Autumn 2021 Wave of SARS-CoV-2

Sikora, D., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10030437 · Cited by 26

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 248

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationPreprint

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263487 · Cited by 11

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose

Yavlinsky, A., Beale, S., Nguyen, V. G., Shrotri, M., Byrne, T., Geismar, C., Fragaszy, E., Hoskins, S., Fong, W. L. E., Navaratnam, A. M. D., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17914.1 · Cited by 10

Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study

Leong, D. P., Zhang, A., Breznik, J. A., Clare, R., Huynh, A., Mushtaha, M., Rangarajan, S., Stacey, H. D., Kim, P. Y., Loeb, M. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281673 · Cited by 10

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose

Sanna, G., Marongiu, A., Firinu, D., Piras, C., Palmas, V., Galdiero, M., Atzori, L., Caria, P., Campagna, M., Perra, A., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01276-x · Cited by 1